血红蛋白水平与取栓卒中患者预后相关:EVT合作队列研究
本研究基于EVT登记的前瞻性多中心队列,纳入9967例接受血管内取栓的缺血性卒中患者,分析血红蛋白水平与3个月功能预后、死亡及症状性颅内出血(sICH)的关系。结果显示贫血与高血红蛋白均独立关联不良预后和死亡,且连续变量呈U形关系,但与sICH无关。
要点
- 贫血(<120 g/L)独立增加不良预后(OR 1.48)和死亡(OR 1.69)风险。
- 中重度贫血(<100 g/L)预后最差:不良预后OR 1.75,死亡OR 2.80。
- 高血红蛋白(女>155、男>170 g/L)亦独立关联不良预后(OR 1.33)和死亡(OR 1.49)。
核心结论
- 贫血越严重及血红蛋白越高,取栓后3个月不良功能预后和死亡风险越高。
- 血红蛋白作为连续变量与死亡和不良预后呈U形关系。
- 血红蛋白水平与症状性颅内出血发生无关联。
研究设计与样本
- 前瞻性多中心队列研究,数据来自EVT登记(EndoVAscular Treatment and ThRombolysis for Ischemic Stroke Patients协作)。
- 共纳入9967例接受血管内取栓治疗的缺血性卒中患者。
主要发现
- 7168例(71.9%)血红蛋白正常,2496例(25.1%)贫血(其中618例[6.2%]为中重度贫血),303例(3%)血红蛋白升高。
- 贫血 vs 正常:不良预后(mRS 3-6)校正OR 1.48(95%CI 1.32-1.66),死亡校正OR 1.69(95%CI 1.50-1.90)。
- 中重度贫血 vs 正常:不良预后校正OR 1.75(95%CI 1.41-2.18),死亡校正OR 2.80(95%CI 2.28-3.43)。
- 血红蛋白升高 vs 正常:不良预后校正OR 1.33(95%CI 1.01-1.74),死亡校正OR 1.49(95%CI 1.09-2.03)。
- 血红蛋白水平与症状性颅内出血(sICH)无显著关联。
临床怎么用
- 取栓术前评估血红蛋白水平有助于识别不良预后高危患者。
- 对贫血(尤其<100 g/L)及血红蛋白升高患者,可考虑作为改善预后的潜在干预靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Anemia and elevated hemoglobin levels (HLs) are frequently found in ischemic stroke patients, and their prognostic meaning is unclear. OBJECTIVES: We aimed to study the effect of HLs on the functional outcome and risk of symptomatic intracranial hemorrhage (sICH) in stroke patients treated with thrombectomy. METHODS: In this prospective multicenter study of the EndoVAscular Treatment and ThRombolysis for Ischemic Stroke Patients Registry, we investigated whether HLs were associated with 3-month poor outcomes (modified Rankin Scale 3-6), mortality, and sICH. HLs were categorized into anemia (<120 g/L; moderate/severe anemia: <100 g/L), normal HL (female: 120-155 g/L; male: 120-170 g/L), and elevated HL (female: >155 g/L; male: >170 g/L). Unadjusted and adjusted odds ratios (ORsadjusted) with 95% CIs were calculated from logistic regression models. Additionally, we calculated fitted conditional mean outcomes for HLs as a continuous variable. RESULTS: Among 9967 endovascular thrombectomy-treated patients, 7168 (71.9%) had normal HLs, 2496 (25.1%) had anemia (of whom 618 [6.2%] had moderate/severe anemia), and 303 (3%) had elevated HLs. Anemia vs normal HLs was independently associated with a poor outcome (ORadjusted 1.48 [95% CI, 1.32-1.66]) and mortality (ORadjusted 1.69 [95% CI, 1.50-1.90]). Moderate/severe anemia had the highest odds of a poor outcome (ORadjusted 1.75 [95% CI, 1.41-2.18]) and mortality (ORadjusted 2.80 [95% CI, 2.28-3.43]). Elevated HLs vs normal HLs were independently associated with a poor outcome (ORadjusted 1.33 [95% CI, 1.01-1.74]) and mortality (ORadjusted 1.49 [95% CI, 1.09-2.03]). HLs were not associated with the occurrence of sICH. HL, as a continuous variable, showed a U-shaped relationship with mortality and poor outcomes. CONCLUSION: More severe anemia and higher HLs are associated with increased likelihood of poor functional outcome and death. They may constitute targets for interventions to improve outcomes.
引用
- Altersberger VL, Beyeler M, Jood K, et al. Anemia and elevated hemoglobin in stroke patients treated with thrombectomy - a cohort study from the EndoVAscular treatment and ThRombolysis for Ischemic Stroke Patients collaboration. J Thromb Haemost. 2026. PMID: 42155692. doi:10.1016/j.jtha.2026.05.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。